iPSC-CM – “Functional and pharmacological differences between the contractility of axoCellsTM iPSC-derived atrial and ventricular cardiomyocytes assessed on the FLEXcyte 96”

In this application note, InnoVitro GmbH and Axol Biosciences Limited show that distinct pharmacological effects can be observed between axoCellsTM atrial and ventricular hiPSC-derived cardiomyocytes when using the FLEXcyte 96 platform to assess contractility, providing a powerful tool to perform in vitro drug screening and disease modelling on subtype-specific hiPSC-derived cardiomyocytes.